Data gathered: April 21
Alternative Data for Cadrenal Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,872 | Sign up | Sign up | Sign up |
| Twitter Mentions | 29 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Cadrenal Therapeutics
None
| Price | $16.33 |
| Target Price | Sign up |
| Volume | 7,360 |
| Market Cap | $31M |
| Year Range | $6.03 - $20.45 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Is Cadrenal Therapeutics (NASDAQ:CVKD) In A Good Position To Deliver On Growth Plans?April 5 - Yahoo |
 |
Q1 Earnings Forecast for CVKD Issued By Zacks Small CapApril 3 - ETF Daily News |
|
Cadrenal Therapeutics Participates in Key Medical and Business Development ConferencesApril 2 - Yahoo |
 |
War Refugee-Turned-CEO Presents Lessons In Grit, Leadership, And SuccessApril 15 - Forbes |
Catastrophic Antiphospholipid Syndrome Market Research 2025-2034, Profiles of Abbott, AbbVie, Boehringer Ingelheim, BMS, Cadrenal, Eli Lily, F. Hoffmann-La Roche, J&J, Merck, Novartis, Pfizer, SanofiApril 9 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 1.7M | -1.7M | -2.4M | -2.4M | -2.180 |
| Q2 '24 | 0 | 1.2M | -1.2M | -2.4M | -2.4M | -2.250 |
| Q1 '24 | 0 | 1.1M | -1.1M | -1.7M | -1.7M | -0.100 |
| Q4 '23 | 720,000 | 570,000 | 140,000 | -1.1M | -1.1M | -0.050 |
| Q3 '23 | 0 | 960,000 | -960,000 | -1M | -1M | -0.080 |
Insider Transactions View All
| MURPHY JOHN RAYMOND filed to buy 614,792 shares at $0.7. October 6 '23 |
| MURPHY JOHN RAYMOND filed to buy 612,123 shares at $0.7. October 6 '23 |
| Pham Quang X filed to buy 3,410,000 shares at $0.9. September 6 '23 |
| Pham Quang X filed to buy 3,370,000 shares at $0.8. September 5 '23 |
| Pham Quang X filed to buy 3,350,000 shares at $0.9. September 5 '23 |
Similar companies
Read more about Cadrenal Therapeutics (CVKD) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Cadrenal Therapeutics?
The Market Cap of Cadrenal Therapeutics is $31M.
What is the current stock price of Cadrenal Therapeutics?
Currently, the price of one share of Cadrenal Therapeutics stock is $16.33.
How can I analyze the CVKD stock price chart for investment decisions?
The CVKD stock price chart above provides a comprehensive visual representation of Cadrenal Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Cadrenal Therapeutics shares. Our platform offers an up-to-date CVKD stock price chart, along with technical data analysis and alternative data insights.
Does CVKD offer dividends to its shareholders?
As of our latest update, Cadrenal Therapeutics (CVKD) does not offer dividends to its shareholders. Investors interested in Cadrenal Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Cadrenal Therapeutics?
Some of the similar stocks of Cadrenal Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.